Small preliminary study suggests Covid rebound is far more common with Paxlovid than without

Study suggests Covid rebound is far more common with Paxlovid than without A small and preliminary study published Monday seems to indicate that patients receiving Paxlovid are far more likely to experience Covid rebound than those who did not take it. Matthew Herper STAT

...

The study’s authors and outside experts emphasize that there is no question that Paxlovid is a useful drug that can help keep patients infected with the SARS-CoV-2 virus from being hospitalized. But some also wondered if the results might be an indicator that the current dosing duration of Paxlovid — daily, for five days — is not long enough.

...